STOCK TITAN

Senseonics Holdings, Inc. - SENS STOCK NEWS

Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.

Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.

The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.

Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.

Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.

Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE American: SENS) reported Q3 2023 financial results, including $6.1M in revenue, completion of a pivotal clinical study, and a new advertising campaign. Gross profit increased to $1.2M, while net loss decreased to $24.1M. The company expects full year 2023 global net revenue to be in the range of $20M to $24M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) to Participate in Stifel 2023 Healthcare Conference, Presenting on Long-Term Implantable CGM Systems for Diabetes Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
-
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) plans to release its Q3 2023 financial results on November 9, 2023. The company is focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes. A conference call will be held to review the performance, which will be webcasted and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings launch new advertising campaign for Eversense E3 CGM System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
Rhea-AI Summary
Senseonics completes ENHANCE Pivotal Clinical Study for Eversense CGM system, aims for FDA approval for 365-day system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
-
Rhea-AI Summary
Senseonics Holdings, Inc. to present at Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences acquisition
Rhea-AI Summary
Senseonics Holdings, Inc. has entered into a $50 million loan facility with Hercules Capital, Inc. The company drew down $25 million upon closing. The loan facility provides increased financial flexibility and strengthens the balance sheet. Senseonics aims to fund its current operating plans and advance its product pipeline. The availability of additional tranches is subject to revenue and gross margin milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none
-
Rhea-AI Summary
Senseonics Holdings, Inc. reported Q2 2023 financial results, including revenue of $4.1 million. They also submitted an application to the FDA for an iCGM designation and received positive coverage from UnitedHealthcare. The company presented positive data at the ADA highlighting the longevity and accuracy of their Eversense System. Senseonics entered into exchange agreements to strengthen their balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
-
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE-American: SENS) will release its second quarter 2023 financial results after market close on August 10, 2023. The company is focused on developing long-term implantable continuous glucose monitoring systems for people with diabetes. A conference call to review performance will be held at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none

FAQ

What is the current stock price of Senseonics Holdings (SENS)?

The current stock price of Senseonics Holdings (SENS) is $0.4598 as of December 20, 2024.

What is the market cap of Senseonics Holdings (SENS)?

The market cap of Senseonics Holdings (SENS) is approximately 287.8M.

What does Senseonics Holdings, Inc. specialize in?

Senseonics specializes in developing and commercializing advanced glucose monitoring systems for diabetes management, featuring the first fully implantable CGM system.

What is the Eversense Continuous Glucose Monitoring (CGM) System?

The Eversense CGM System is a breakthrough glucose monitoring solution that includes a small sensor implanted under the skin, an external smart transmitter, and a mobile app for real-time glucose data.

How long can the Eversense CGM System monitor glucose levels?

The Eversense CGM System can continuously monitor glucose levels for up to 180 days, offering a long-term solution compared to traditional short-term CGMs.

What is the Eversense Payment Assistance and Simple Savings (PASS) Program?

The PASS Program is designed to make the Eversense E3 CGM System more affordable by offering eligible individuals in the U.S. the system at a reduced cost of $99 for each six-month period.

How does Senseonics' CGM technology benefit people with diabetes?

The CGM technology provides highly accurate, stable, and long-term glucose monitoring, enabling people with diabetes to manage their condition confidently and with ease.

Where is Senseonics Holdings, Inc. headquartered?

Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, USA.

Who are Senseonics' key partners?

Senseonics has key partnerships with companies like Ascensia Diabetes Care, which helps in the global distribution and accessibility of their products.

How can I learn more about the Eversense CGM System?

You can visit Ascensia Diabetes Care's website or contact their support line to get detailed information about the Eversense CGM System and eligibility for the PASS Program.

Is the Eversense CGM System available outside the United States?

Yes, the Eversense CGM System is available globally, and Senseonics generates a significant portion of its revenue from markets outside the United States.

What is the mission of Senseonics Holdings, Inc.?

The mission of Senseonics is to transform the lives of people with diabetes through innovative, long-term implantable glucose management technology.

Senseonics Holdings, Inc.

NYSE:SENS

SENS Rankings

SENS Stock Data

287.78M
563.15M
4.86%
10.01%
6.64%
Medical Devices
Industrial Instruments for Measurement, Display, and Control
Link
United States of America
GERMANTOWN